Cognistx to Collaborate on AI Initiative to Improve the Development of Psychedelic Medicine for the Treatment of Mental Health Illnesses
Cognistx to Collaborate on AI Initiative to Improve the Development of Psychedelic Medicine for the Treatment of Mental Health Illnesses Share Article Cognistx and MagicMed Industries Inc. will develop PsyAI™, a tool designed to streamline pharmaceutical design in an effort to accelerate the modernization of psychedelic medicines. Cognistx “The convergence of AI and psychedelic medicine will result in a medical renaissance – all to benefit the treatment of mental health conditions,” said Cognistx CEO Sanjay Chopra. “It’s very exciting to be at the nexus of this convergence of medi...